 |
|
|
Industry News
-
Juno Therapeutics presents TRANSCEND NHL 001 trial data
Juno Therapeutics reported data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B cell non-Hodgkin lymphom. TRANSCEND NHL 001 is a dose-finding study of JCAR017, which is administered following fludarabine/cyclophosphamide lymphodepletion.
June 17, 2017
More...
|
|
|
|